Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699930 · ClinicalTrials.gov registry record · NA
Impact of Neuromodulation on Language Impairments in Stroke Patients
A NA study, sponsored by Casa Colina Hospital and Centers for Healthcare.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT03699930: Completed NA study, sponsored by Casa Colina Hospital and Centers for Healthcare.
NCT03699930 is a NA study that has completed, run by Casa Colina Hospital and Centers for Healthcare. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03699930, a NA study, has completed, sponsored by Casa Colina Hospital and Centers for Healthcare.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
Up to 40% of stroke survivors suffer from aphasia, making recovery of language abilities a top priority in stroke rehabilitation. Conventional speech and language therapy may have limited effectiveness. Leveraging multimodal data (behavioral, neuroimaging, and genetics), this study aims to 1) evaluate the efficacy of combining tDCS with speech therapy, 2) examine neural changes associated with recovery, 3) identify factors influencing response to treatment.
Primary Outcome
WAB-R is an instrument for assessing the language function of adults with suspected neurological disorders as a result of a stroke.
Interventions
- DEVICE tDCS
- BEHAVIORAL Speech and language therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2023-01-01 |
| Phase | NA |
What the finished NCT03699930 record still lists
NCT03699930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which tDCS is the first listed.
NCT03699930 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03699930 about?
NCT03699930 is a clinical study titled "Impact of Neuromodulation on Language Impairments in Stroke Patients". Up to 40% of stroke survivors suffer from aphasia, making recovery of language abilities a top priority in stroke rehabilitation. Conventional speech and language therapy may have limited effectiveness. Leveraging multimodal data (behavioral, neuroimaging, and genetics), this study aims to 1) evalua...
What is the current status of trial NCT03699930?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2018-01-01. Estimated completion is 2023-01-01.
What interventions are being tested in trial NCT03699930?
The interventions under investigation include: tDCS (DEVICE), Speech and language therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT03699930?
This trial is sponsored by Casa Colina Hospital and Centers for Healthcare, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03699930's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI